Inspiringly, amivantamab plus carboplatin–pemetrexed chemotherapy with and without lazertinib also demonstrated antitumor activity in patients with osimertinib refractory EGFR‐mutated advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.